Autosomal Dominant Polycystic Kidney Disease (ADPKD)

ADPKD is the most common inherited kidney disease, caused by mutations in PKD1 or PKD2 leading to progressive cyst formation, kidney enlargement, and eventual kidney failure. Extra-renal manifestations include liver cysts, intracranial aneurysms, and cardiac valve abnormalities.

Symptoms

• Flank pain, abdominal fullness
• Hematuria, kidney stones
• Hypertension (often early and severe)
• Recurrent UTIs
• Progressive decline in eGFR leading to ESRD in adulthood
• Liver cysts causing discomfort, hernias, diverticulosis

Diagnosis

• Family history + ultrasound criteria (Ravine/Pei) based on age
• CT or MRI to assess total kidney volume (TKV)
• Genetic testing for atypical presentations or family planning
• Screen for extrarenal issues (liver cysts, intracranial aneurysm in high-risk patients)

Management

Blood Pressure & Lifestyle

• Target BP <110/75 if tolerated; ACE inhibitors/ARBs preferred
• Low-sodium diet (<2 g/day), maintain healthy weight, regular exercise
• Limit caffeine, avoid nephrotoxins (NSAIDs)
• Adequate hydration; some protocols advise >3 L/day to suppress vasopressin (individualized)

Disease-Modifying Therapy

• Tolvaptan (vasopressin V2 receptor antagonist) slows kidney enlargement and eGFR decline in rapidly progressive ADPKD
• Requires monitoring for liver toxicity; manage aquaretic side effects (polyuria, thirst)
• Clinical trials exploring somatostatin analogs, mTOR inhibitors, CFTR modulators

Symptom Control

• Manage pain with non-NSAID analgesics; consider cyst aspiration or sclerotherapy
• Treat UTIs promptly; prophylaxis for recurrent infections
• Manage nephrolithiasis; encourage hydration, metabolic evaluation

ESRD Planning

• Early education on dialysis modalities and kidney transplantation
• Living donor transplantation often considered

Extrarenal Monitoring

• Liver cyst management (aspiration/sclerotherapy, resection)
• Screen intracranial aneurysms with MR angiography in patients with family history, prior rupture, or high-risk professions
• Echo for valve disease (mitral valve prolapse, aortic regurgitation)

Living with ADPKD

• Track BP, eGFR, TKV, medications, fluids, pain episodes, UTIs, and imaging
• Plan career/life decisions with knowledge of CKD progression
• Genetic counseling for family planning (preimplantation genetic testing)
• Mental health support; chronic disease and transplant planning are stressful

Complications

• CKD progression to ESRD
• Intracranial aneurysm rupture, subarachnoid hemorrhage
• Cardiac valve disease
• Hernias, diverticulitis
• Hepatic cyst infection/hemorrhage

Research & Future Directions

Research targets cAMP signaling, metabolic reprogramming, fibrosis inhibition, and gene editing to halt cyst growth earlier.

Experimental & Emerging Treatments

• Somatostatin Analogues (octreotide, lanreotide): Mixed data; ongoing research for liver cysts and kidney growth.
• mTOR/AMPK Modulators: Metformin being studied for cyst suppression.
• RNA Interference & Gene Editing: CRISPR/Cas9 targeting PKD genes in preclinical models.
• Digital Twin Modeling: Predicts individual growth rates and tolvaptan benefit.

Track ADPKD with Diagnoza.care

Plan for Decades, Not Months – Log BP readings, tolvaptan dosing, labs (eGFR, liver function), imaging (TKV), UTIs, pain episodes, hydration goals, and transplant evaluations; capture side effects; and let the AI companion remind you of monitoring and hydration targets.

---

Medical Disclaimer: Informational only. Work with your nephrologist/PKD clinic for BP control, tolvaptan eligibility, extrarenal screening, and transplant/dialysis planning. Sources: Kidney Disease: Improving Global Outcomes (KDIGO), PKD Foundation, National Kidney Foundation